271 related articles for article (PubMed ID: 18442297)
1. Malignancy in kidney transplant recipients.
Kapoor A
Drugs; 2008; 68 Suppl 1():11-9. PubMed ID: 18442297
[TBL] [Abstract][Full Text] [Related]
2. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
Campistol JM; Albanell J; Arns W; Boletis I; Dantal J; de Fijter JW; Mortensen SA; Neumayer HH; Øyen O; Pascual J; Pohanka E; Schena FP; Serón D; Sparacino V; Chapman JR
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
[TBL] [Abstract][Full Text] [Related]
3. Clinical insights for cancer outcomes in renal transplant patients.
Alberú J
Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
[TBL] [Abstract][Full Text] [Related]
4. Is there a role for proliferation signal/mTOR inhibitors in the prevention and treatment of de novo malignancies after heart transplantation? Lessons learned from renal transplantation and oncology.
Valantine H
J Heart Lung Transplant; 2007 Jun; 26(6):557-64. PubMed ID: 17543777
[TBL] [Abstract][Full Text] [Related]
5. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.
Gutierrez-Dalmau A; Campistol JM
Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218
[TBL] [Abstract][Full Text] [Related]
6. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients.
Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ
Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413
[No Abstract] [Full Text] [Related]
7. Malignancy after transplantation.
Buell JF; Gross TG; Woodle ES
Transplantation; 2005 Oct; 80(2 Suppl):S254-64. PubMed ID: 16251858
[TBL] [Abstract][Full Text] [Related]
8. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy.
Klintmalm GB; Saab S; Hong JC; Nashan B
Clin Transplant; 2014 Jun; 28(6):635-48. PubMed ID: 24628264
[TBL] [Abstract][Full Text] [Related]
9. The change of immunosuppressive regimen from calcineurin inhibitors to mammalian target of rapamycin (mTOR) inhibitors and its effect on malignancy following heart transplantation.
Saber-Moghaddam N; Nomani H; Sahebkar A; Johnston TP; Mohammadpour AH
Int Immunopharmacol; 2019 Apr; 69():150-158. PubMed ID: 30711744
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppression with mammalian target of rapamycin inhibitor and incidence of post-transplant cancer in kidney transplant recipients.
Opelz G; Unterrainer C; Süsal C; Döhler B
Nephrol Dial Transplant; 2016 Aug; 31(8):1360-7. PubMed ID: 27190384
[TBL] [Abstract][Full Text] [Related]
11. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.
Kauffman HM; Cherikh WS; Cheng Y; Hanto DW; Kahan BD
Transplantation; 2005 Oct; 80(7):883-9. PubMed ID: 16249734
[TBL] [Abstract][Full Text] [Related]
12. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
Tönshoff B; Höcker B
Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
[TBL] [Abstract][Full Text] [Related]
13. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
Geissler EK
Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection.
Marcén R
Drugs; 2009 Nov; 69(16):2227-43. PubMed ID: 19852526
[TBL] [Abstract][Full Text] [Related]
15. Everolimus: an immunosuppressive agent in transplantation.
Patel JK; Kobashigawa JA
Expert Opin Pharmacother; 2006 Jul; 7(10):1347-55. PubMed ID: 16805720
[TBL] [Abstract][Full Text] [Related]
16. The role of proliferation signal inhibitors in post-transplant malignancies.
Gutiérrez-Dalmau A; Campistol JM
Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i11-6. PubMed ID: 17360768
[TBL] [Abstract][Full Text] [Related]
17. A drug safety evaluation of everolimus in kidney transplantation.
Holdaas H; Midtvedt K; Åsberg A
Expert Opin Drug Saf; 2012 Nov; 11(6):1013-22. PubMed ID: 22954349
[TBL] [Abstract][Full Text] [Related]
18. Timing of mTORI usage and outcomes in kidney transplant recipients.
Lim LM; Kung LF; Kuo MC; Huang AM; Kuo HT
Int J Med Sci; 2021; 18(5):1179-1184. PubMed ID: 33526978
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Mammalian Target of Rapamycin Inhibitor Use in Heart and Lung Transplantation.
Fine NM; Kushwaha SS
Transplantation; 2016 Dec; 100(12):2558-2568. PubMed ID: 27495747
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients.
Pescovitz MD; Govani M
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S16-21. PubMed ID: 11583940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
